Medpace Holdings, INC Form 4 insider transactions

Cornelius P. McCarthy III, a director at Medpace Holdings, exercised stock options on September 30, 2024, acquiring 62 shares of common stock.

Director Robert Kraft of Medpace Holdings reports the vesting and conversion of restricted stock units into common stock.

Director Brian T. Carley reported the vesting of 78 restricted stock units of Medpace Holdings, Inc. on September 30, 2024.

Director Robert Kraft exercised stock options and sold shares of Medpace Holdings (MEDP) on August 22nd and 23rd, 2024.

Executive VP of Operations at Medpace Holdings, Susan Burwig, exercised stock options and was granted restricted stock units (RSUs) according to a recent SEC Form 4 filing.

Medpace Holdings President Jesse J. Geiger reported the acquisition of 10,000 restricted stock units (RSUs) on August 5, 2024, vesting in full on August 5, 2029, subject to continued employment.

Kevin M. Brady, CFO & Treasurer of Medpace Holdings, Inc., reports the disposition of 6,000 shares of common stock and acquisition of 7,500 restricted stock units.

Stephen P. Ewald, General Counsel & Corp. Secy. of Medpace Holdings, Inc., reports the acquisition of 7,500 restricted stock units.

August J. Troendle, CEO of Medpace Holdings, reports the acquisition of 50,000 stock options and indirect beneficial ownership of 4,733,019 shares through Medpace Investors, LLC.

Director Dani S. Zander acquired stock options in Medpace Holdings, Inc. on July 1, 2024.

Cornelius P. McCarthy III, a director at Medpace Holdings, exercised stock options and acquired 62 shares of common stock on June 30, 2024.

Director Robert O. Kraft reports the vesting of restricted stock units into Medpace Holdings common stock.

Director Brian T. Carley reported the vesting and conversion of restricted stock units into Medpace Holdings, Inc. common stock.

Susan Burwig, Executive VP of Operations at Medpace Holdings, sold 7,681 shares of common stock on June 5, 2024.

August J. Troendle, CEO of Medpace Holdings, reported the sale of company stock in two transactions on May 24 and May 28, 2024.

August J. Troendle, CEO of Medpace Holdings, reported selling 55 shares of common stock at $400 per share on May 22, 2024.

Medpace Holdings CEO August J. Troendle sold 4,020 shares of common stock at a weighted average price of $400.19 on May 20, 2024.

Cornelius P. McCarthy III, a director of Medpace Holdings, Inc., acquired stock options on May 17, 2024.

Director Ashley M. Keating acquired stock options in Medpace Holdings, Inc. on May 17, 2024.

Director Femida H. Gwadry-Sridhar acquired stock options in Medpace Holdings, Inc. on May 17, 2024.

Robert O. Kraft, a director at Medpace Holdings, Inc., acquired stock options on May 17, 2024.

Director Brian T. Carley of Medpace Holdings, Inc. reports acquisition of stock options.

Director Fred B. Davenport Jr. of Medpace Holdings, Inc. reports the acquisition of stock options.

Medpace Holdings CEO August J. Troendle sold shares of the company's common stock on May 15 and 16, 2024, according to a Form 4 filing with the SEC.

Medpace Holdings CEO August J. Troendle reported the sale of 4,956 shares of common stock at a weighted average price of $402.89 on May 10, 2024.

Medpace Holdings CEO August J. Troendle reported the sale of company stock in two transactions on May 8 and May 9, 2024.

Medpace Holdings CEO August J. Troendle reports selling shares of the company's common stock on May 6th and 7th, 2024.

Medpace Holdings CEO August J. Troendle reports selling shares of common stock on May 1st and 2nd, 2024.

Medpace Holdings CEO August J. Troendle reports selling shares of common stock on April 29 and April 30, 2024.

Robert O. Kraft, a director at Medpace Holdings, exercised stock options on March 31, 2024, acquiring 72 shares of common stock.